專家簡介:王禹超

This entry was posted in 專家檔案 on by

人體是非常複雜的系統，舉例來說，同樣是得肺腺癌的病人，有的人用某些藥物治療會有很好的療效，有的卻毫無反應；有的人腫瘤會轉移到腦部，有的人雖然會轉移，卻轉移到腦以外的其他器官。有鑑於此，我的實驗室的研究方向聚焦於生醫數據分析與人工智慧之臨床應用、轉譯生物資訊與系統生物學。我們分析各式各樣的生醫數據，尤其是次世代定序所產生的基因體及轉錄體等體學(omics)資料，希望藉由資料探勘、機器學習等生醫資訊方法探討造成不同表現型背後的差異，並藉由這些基因、蛋白質等分子層次的差異（基因突變、基因表現量、DNA甲基化等差異）建構預測或分類模型，協助臨床醫師進行更細微的病人分群，以期可以達到精準醫學的應用及實踐。因此我們與臨床醫師及生物學家進行很多跨領域的合作，以系統生物學及資料科學的角度，系統化的探討疾病的致病機制並鑑別診斷性及預測性生物標記。近期研究主題著重於利用多體學分析探索具有潛力的免疫檢查點抑制劑預測生物標記，希望鑑別出的預測生物標記可以協助醫師進行臨床決策，此外也希望經由顯著的基因及臨床特徵的鑑別可以讓我們解析腫瘤、免疫系統及腫瘤微環境的複雜交互作用，對於癌症的機轉有更深一層的理解。

研究領域：

生醫數據分析與人工智慧之臨床應用、轉譯生物資訊、系統生物學

學歷：

國立清華大學電機博士

國立清華大學電機學士

經歷：

國立陽明交通大學生物醫學資訊研究所副教授

國立陽明大學生物醫學資訊研究所副教授

國立陽明大學生物醫學資訊研究所助理教授

國立清華大學博士後研究

專長：

系統生物學及Omics資料分析

生物資訊學

計算生物學

研究成果：

  1. Yeh YC, Lei HJ, Chen MH, Ho HL, Chiu LY, Li CP, Wang YC, “C-reactive protein (CRP) is a promising diagnostic immunohistochemical marker for intrahepatic cholangiocarcinoma and is associated with better prognosis” American Journal of Surgical Pathology, 41(12):1630-1641, 2017.
  2. Lyu GY, Yeh YH, Yeh YC, Wang YC, “Mutation load estimation model as a predictor of the response to cancer immunotherapy” npj Genomic Medicine, 3:12, 2018.
  3. Yeh YC, Ho HL, Wu YC, Pan CC, Wang YC, Chou TY, “AKT1 internal tandem duplications and point mutations are the genetic hallmarks of sclerosing pneumocytoma” Modern Pathology, 33(3):391-403, 2020.
  4. Tan KT, Yeh CN, Chang YC, Cheng JH, Fang WL, Yeh YC, Wang YC, Hsu DS, Wu CE, Lai JI, Chang PM, Chen MH, Lu ML, Chen SJ, Chao Y, Hsiao M, Chen MH, “PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy” Journal for ImmunoTherapy of Cancer, 8:e000485, 2020.
  5. Pan CC, Yeh YC, Wang YC, Chang YH, “Differential expression analysis of clear cell renal cell carcinomas in The Cancer Genome Atlas distinguishes an aggressive subset enriched with chromosomes 7 and 12 gains” Histopathology, 76(7):950-958, 2020.
  6. Pan YR†, Wu CE†, Wang YC†, Yeh YC, Lu ML, Hung YP, Chao Y, Yeh DW, Lin CH, Hsieh JC, Chen MH, Yeh CN, “Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response” Clinical & Translational Immunology, 9:e1145, 2020. †co-first author
  7. Wu CE, Yeh DW, Pan YR, Huang WK, Chen MH, Chang JW, Chen JS, Wang YC, Yeh CN, “Chromosomal instability may not be a predictor for immune checkpoint inhibitors from comprehensive bioinformatics analysis” Life (Basel), 10(11):276, 2020.
  8. Huang YF, Chang CH, Chen PJ, Lin IH, Tsai YA, Chen CF, Wang YC, Huang WY, Tsai MS, Chen ML, “Prenatal bisphenol A exposure, DNA methylation, and low birth weight: a pilot study in Taiwan” International Journal of Environmental Research and Public Health, 18(11):6144, 2021.
  9. Chiu TY, Lin RW, Huang CJ, Yeh DW, Wang YC, “DNA damage repair gene set as a potential biomarker for stratifying patients with high tumor mutational burden” Biology (Basel), 10(6):528, 2021.
  10. Huang CJ, Wang LH, Wang YC, “Identification of therapeutic targets for the selective killing of HBV-positive hepatocytes” Journal of Personalized Medicine, 11(7):649, 2021.
  11. Yeh YC, Ho HL, Lin CI, Chou TY, Wang YC, “Whole-exome sequencing of Epstein–Barr virus-associated pulmonary carcinoma with low lymphocytic infiltration reveals molecular features similar to those of classic pulmonary lymphoepithelioma-like carcinoma: Evidence to support grouping together as one disease entity” American Journal of Surgical Pathology, 45(11):1476-1486, 2021.
  12. Lin YY†, Wang YC†, Yeh DW, Hung CY, Yeh YC, Ho HL, Mon HC, Chen MY, Wu YC, Chou TY, “Gene expression profile in primary tumor is associated with brain-tropism of metastasis from lung adenocarcinoma” International Journal of Molecular Sciences, 22(24):13374, 2021. †co-first author
  13. Yu HY, Li CP, Huang YH, Hsu SJ, Wang YP, Hsieh YC, Fang WL, Huang KH, Li AF, Lee RC, Lee KL, Wu YH, Lai IC, Yang WC, Hung YP, Wang YC, Chen SH, Chen MH, Chao Y, “Microsatellite instability, Epstein–Barr virus, and programmed cell death ligand 1 as predictive markers for immunotherapy in gastric cancer” Cancers, 14(1):218, 2022.
  14. Pan CC, Tseng CE, Kuroda N, Yano M, Yasuda M, Nagashima Y, Yeh YC, Wang YC, Chang YH, Epstein JI, “Molecular characterization of metanephric adenoma, epithelial Wilms tumor and overlap lesions: An integrated whole exome and transcriptome sequencing analysis” Applied Immunohistochemistry & Molecular Morphology, 30(4):257-263, 2022
  15. Sanmarco LM†, Chao CC†, Wang YC†, Kenison JE†, Li Z, Rone JM, Rejano-Gordillo CM, Polonio CM, Gutierrez-Vazquez C, Piester G, Plasencia A, Li L, Giovannoni F, Lee HG, Faust Akl C, Wheeler MA, Mascanfroni I, Jaronen M, Alsuwailm M, Hewson P, Yeste A, Andersen BM, Franks DG, Huang CJ, Ekwudo M, Tjon EC, Rothhammer V, Takenaka M, de Lima KA, Linnerbauer M, Guo L, Covacu R, Queva H, Fonseca-Castro PH, Bladi MA, Cox LM, Hodgetts KJ, Hahn ME, Mildner A, Korzenik J, Hauser R, Snapper SB, Quintana FJ, “Identification of environmental factors that promote intestinal inflammation” Nature, 611(7937):801-809, 2022. †co-first author
  16. Chen TH, Chen MH, Hung YP, Chiang NJ, Huang KH, Lin YH, Lin RW, Chao Y, Li AF, Yu HY, Huang HE, Yeh YC, Wang YC, Fang WL*, “Elevated PD-L1 expression and microsatellite instability in elderly patients with gastric cancer” Journal of Immunotherapy, 46(3):111-119, 2023.

Leave a comment